2. Search Result
Search Result
Results for "

pulmonary arterial hypertension (PAH)

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

2

Peptides

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14184S
    Macitentan-d4

    ACT-064992-d4

    		 Isotope-Labeled Compounds Endothelin Receptor Apoptosis Cardiovascular Disease
    Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].
    Macitentan-d4
  • HY-A0126A
    Epoprostenol sodium

    Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan

    		 Endogenous Metabolite Apoptosis Cardiovascular Disease
    Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium
  • HY-14184
    Macitentan
    Maximum Cited Publications
    11 Publications Verification

    ACT-064992

    		 Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan
  • HY-128593
    TPN171

    		Phosphodiesterase (PDE) Cardiovascular Disease
    TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .
    TPN171
  • HY-14184A
    Macitentan (n-butyl analogue)

    		Endothelin Receptor Cardiovascular Disease Endocrinology
    Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan (n-butyl analogue)
  • HY-P0012A
    Aviptadil acetate
    1 Publications Verification

    Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil acetate
  • HY-170435
    PDE5-IN-13

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-13 inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for the treatment of PAH (pulmonary arterial hypertension). PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 has reasonable drug-like profiles .
    PDE5-IN-13
  • HY-115477
    Brilaroxazine hydrochloride

    RP5063 hydrochloride

    		 Others Cardiovascular Disease
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-167906
    Lunamarine

    		Bacterial Phosphodiesterase (PDE) Metabolic Disease
    Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .
    Lunamarine
  • HY-A0126AR
    Epoprostenol sodium (Standard)

    Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)

    		 Endogenous Metabolite Cardiovascular Disease
    Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium (Standard)
  • HY-14184R
    Macitentan (Standard)

    		Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology Cancer
    Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
    Macitentan (Standard)
  • HY-155737
    ET receptor antagonist 1

    		Estrogen Receptor/ERR Cardiovascular Disease
    ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
    ET receptor antagonist 1
  • HY-155738
    ET receptor antagonist 2

    		Estrogen Receptor/ERR Cardiovascular Disease
    ET receptor antagonist 2 (compound 16j) is an orally active ET receptor antagonist (IC50=0.22 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 2 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
    ET receptor antagonist 2
  • HY-155739
    ET receptor antagonist 3

    		Estrogen Receptor/ERR Cardiovascular Disease
    ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC50=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model .
    ET receptor antagonist 3
  • HY-P0012
    Aviptadil
    1 Publications Verification

    Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)

    		 SARS-CoV Infection Inflammation/Immunology
    Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .
    Aviptadil
  • HY-101124
    Rodatristat ethyl

    KAR5585

    		 Tryptophan Hydroxylase 5-HT Receptor Cardiovascular Disease
    Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH) .
    Rodatristat ethyl
  • HY-153248
    PBR28

    		Others Others
    PBR28 is an TSPO modulator, which can be used for prevention research of Pulmonary Arterial Hypertension (PAH). PBR28 can be used to trace 18 KDa transporter (TSPO) by adding radioactive labeling, which plays an important role in brain positron emission tomography (PET) imaging studies .
    PBR28
  • HY-129851
    NTP42

    		Prostaglandin Receptor Cardiovascular Disease
    NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .
    NTP42
  • HY-168178
    Hsp110-STAT3 interaction-IN-2

    		HSP STAT Cardiovascular Disease
    Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research .
    Hsp110-STAT3 interaction-IN-2
  • HY-131973
    PDE10A-IN-2 hydrochloride

    		Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research .
    PDE10A-IN-2 hydrochloride
  • HY-149316
    Smurf1-IN-1

    		E1/E2/E3 Enzyme Cardiovascular Disease
    Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC50 of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .
    Smurf1-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: